Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial

Radiotherapy and Oncology

Volumn 108, Issue 1, 2013, Pages 40-47

  Eustace, Amanda ^a   Irlam, Joely J ^a   Taylor, Janet ^a,c   Denley, Helen ^d   Agrawal, Shailesh ^d   Choudhury, Ananya ^b   Ryder, David ^b   Ord, Jonathan J ^f   Harris, Adrian L ^f   Rojas, Ana M ^e   Hoskin, Peter J ^e   West, Catharine M L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Biomarker; Bladder cancer; Carbogen and nicotinamide; Hypoxic modification; Necrosis; Radiotherapy

Indexed keywords

CARBOGEN; CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; NICOTINAMIDE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER RADIOTHERAPY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPOXIA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; NECROSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

BIOMARKER; BLADDER CANCER; CARBOGEN AND NICOTINAMIDE; HYPOXIC MODIFICATION; NECROSIS; RADIOTHERAPY;

AGED; AGED, 80 AND OVER; CARBON DIOXIDE; CARBONIC ANHYDRASE IV; CELL HYPOXIA; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MALE; MIDDLE AGED; NECROSIS; NIACINAMIDE; OXYGEN; RISK; URINARY BLADDER NEOPLASMS;

EID: 84883193045     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.05.017     Document Type: Article

References (31)

1. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
2. J. Dunst, C. Rodel, A. Zietman, K.M. Schrott, R. Sauer, and W.U. Shipley Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy Semin Surg Oncol 20 2001 24 32
3. C. Rodel, G.G. Grabenbauer, and R. Kuhn Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results J Clin Oncol 20 2002 3061 3071
4. P.J. Hoskin, A.M. Rojas, S.M. Bentzen, and M.I. Saunders Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma J Clin Oncol 28 2010 4912 4918
5. J. Overgaard, J.G. Eriksen, M. Nordsmark, J. Alsner, and M.R. Horsman Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial Lancet Oncol 6 2005 757 764
6. J.H. Kaanders, K.I. Wijffels, and H.A. Marres Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer Cancer Res 62 2002 7066 7074
7. D. Rischin, R.J. Hicks, and R. Fisher Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2006 2098 2104
8. K. Toustrup, B.S. Sorensen, P. Lassen, C. Wiuf, J. Alsner, and J. Overgaard Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck Radiother Oncol 102 2012 122 129
9. K. Toustrup, B.S. Sorensen, and M. Nordsmark Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer Cancer Res 71 2011 5923 5931
10. G.O. Janssens, S.E. Rademakers, and C.H. Terhaard Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial J Clin Oncol 30 2012 1777 1783
11. P.J. Hoskin, A. Sibtain, F.M. Daley, and G.D. Wilson GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON Br J Cancer 89 2003 1290 1297
12. V. Palit, R.M. Phillips, R. Puri, T. Shah, and M.C. Bibby Expression of HIF-1alpha and Glut-1 in human bladder cancer Oncol Rep 14 2005 909 913
13. J.J. Ord, S. Agrawal, and T.P. Thamboo An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer J Urol 178 2007 677 682
14. J. Bussink, A.J. van der Kogel, and J.H. Kaanders Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer Lancet Oncol 9 2008 288 296
15. V.V. Iakovlev, M. Pintilie, A. Morrison, A.W. Fyles, R.P. Hill, and D.W. Hedley Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX Lab Invest 87 2007 1206 1217
16. D.E. Thrall, G.L. Rosner, C. Azuma, M.C. McEntee, and J.A. Raleigh Hypoxia marker labelling in tumor biopsies: quantification of labelling variation and criteria for biopsy sectioning Radiother Oncol 44 1997 171 176
17. M. Remzi, A. Haitel, and V. Margulis Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients BJU Int 103 2009 307 311
18. S. Kruger, F. Noack, A. Bohle, and A.C. Feller Histologic tumor growth pattern is significantly associated with disease-related survival in muscle-invasive transitional cell carcinoma of the urinary bladder Oncol Rep 12 2004 609 613
19. A.L. Harris Hypoxia - a key regulatory factor in tumour growth Nat Rev Cancer 2 2002 38 47
20. A.K. Witkiewicz, D. Whitaker-Menezes, and A. Dasgupta Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers Cell Cycle 11 2012
21. W.E. Mesker, G.J. Liefers, and J.M. Junggeburt Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients Cell Oncol 31 2009 169 178
22. E.F. Courrech Staal, M.W. Wouters, and J.W. van Sandick The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer 46 2010 720 728
23. E.M. de Kruijf, J.G. van Nes, and C.J. van de Velde Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients Breast Cancer Res Treat 125 2011 687 696
24. A.M. Moorman, R. Vink, H.J. Heijmans, J. van der Palen, and E.A. Kouwenhoven The prognostic value of tumour-stroma ratio in triple-negative breast cancer Eur J Surg Oncol 38 2012 307 313
25. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184
26. R.F. Youssef, and Y. Lotan Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer Sci World J 11 2011 369 381
27. C.M. Hoff, H.S. Hansen, and M. Overgaard The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - results from the randomized DAHANCA 5 study Radiother Oncol 98 2011 28 33
28. R. Zigeuner, S.F. Shariat, and V. Margulis Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract Eur Urol 57 2010 575 581
29. M.I. Koukourakis, S.M. Bentzen, and A. Giatromanolaki Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial J Clin Oncol 24 2006 727 735
30. H. De Schutter, W. Landuyt, E. Verbeken, L. Goethals, R. Hermans, and S. Nuyts The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy BMC Cancer 5 2005 42
31. M.R. Horsman, and A.J. Van der Kogel Therapeutic approaches to tumour hypoxia M. Joiner, A.J. Van der Kogel, Basic clinical radiobiology 2009 Hodder Arnold London 233 245